Scheithauer BW, Sano T, Kovacs KT, Young WF Jr, Ryan N, Randall RV, 1990 The pituitary gland in pregnancy: a clinicopathologic and immunohistochemical study of 69 cases. Mayo Clin Proc 64: 461–474.
Gonzalez JG, Elizondo G, Saldivar D, Nanez H, Todd LE, Villarreal JZ, 1988 Pituitary gland growth during normal pregnancy: an in vivo study using magnetic resonance imaging. Am J Med 85: 217–220.
Goluboff LG, Ezrin C, 1969 Effect of pregnancy on the somatotroph and the prolactin cell of the human adenohypophysis. J Clin Endocrinol Metab 29: 1533–1538.
Friesen HG, Fournier P, Desjardins P, 1973 Pituitary prolactin in pregnancy and normal and abnormal lactation. Clin Obstet Gynecol 16: 25–45.
Erdheim J, Stumme E, 1909 über die Schwangerschaftsveränderung der Hypophyse. Beitr Pathol Anat Allg Pathol 46: 1–132.
Aubert ML, Grumbach MM, Kaplan SL, 1974 Heterologous radioimmunoassay for plasma human prolactin (hPRL); values in normal subjects, puberty, pregnancy and pituitary disorders. Acta Endocrinol 77: 460–476.
Biswas S, Rodeck CH, 1976 Plasma prolactin levels during pregnancy. Br J Obstet Gynaecol 83: 683–687.
Asa SL, Penz G, Kovacs K, Ezrin C, 1982 Prolactin cells in the human pituitary. A quantitative immunocytochemical analysis. Arch Pathol Lab Med 106: 360–363.
Stefaneanu L, Kovacs K, Lloyd RV, et al, 1992 Pituitary lactotrophs and somatotrophs in pregnancy: a correlative in situ hybridization and immunocytochemical study. Virchows Archiv B Cell Pathol 62: 291–296.
Erikson L, 1989 Growth hormone in human pregnancy. Maternal 24-hour serum profiles and experimental effects of continuous GH secretion. Acta Obstet Gynecol Scand Suppl 147: 1–38.
Rotondo F, Scheithauer BW, Kovacs K, Bell DC, 2009 Rab 3B immunoexpression in human pituitary adenomas. Appl Immunohistochem Mol Morphol 17: 185–188.
Rotondo F, Sharma S, Scheithauer BW, et al, 2010 Endoglin and CD-34 immunoreactivity in the assessment of microvessel density in normal pituitary and adenoma subtypes. Neoplasma 57: 590–593.
Lloyd RV, Scheithauer BW, Kuroki T, Vidal S, Kovacs K, Stefaneanu L, 1999 Vascular endothelial growth factor (VEGF) expression in human pituitary adenomas and carcinomas. Endocr Pathol 10: 229–235.
Folkman J, 1990 What is the evidence that tumors are angiogenesis dependent? J NatL Cancer Inst 82: 4–6.
Denekamp J, 1993 Angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy. Br J Radiol 66: 181–196.
Furuya M, Yonemitsu Y, 2008 Cancer neovascularization and proinflammatory microenvironments. Curr Cancer Drug Targets 8: 253–265.
Pang RW, Poon RT, 2006 Clinical implications of angiogenesis in cancers. Vasc Health Risk Manag 2: 97–108.
Eichhorn ME, Kleespies A, Angele MK, Jaunch KW, Bruns CJ, 2007 Angiogenesis in cancer: molecular mechanisms, clinical impact. Langenecks Arch Surg 392: 371–379.
Ribatti D, 2004 The involvement of endothelial progenitor cells in tumor angiogenesis. J Cell Mol Med 8:294–300.
Schatteman GC, Awad O, 2004 Hemangioblasts, angioblasts and adult endothelial cell progenitors. Anat Rec A Discov Mol Cell Evol Biol 276: 13–21.
Dome B, Timar J, Ladanyi A, et al, 2009 Circulating endothelial cells, bone-marrow-derived endothelial progenitor cells and proangiogenic hematopoietic cells in cancer: from biology to therapy. Crit Rev Oncol Hematol 69: 108–124.
Bussolino F, Mantovani A, Persico G, 1997 Molecular mechanisms of blood vessel formation. Trends Biochem Sci 22: 251–256.
Risau W. Mechanisms of angiogenesis. Nature 386: 671–674.
Hiraoka N, Allen E, Apel IJ, Gyetko MR, Weiss SJ, 1998 Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins. Cell 95: 365–377.
D’Amato RJ, Loughnan MS, Flynn E, Folkman J, 1994 Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91: 4082–4085.
Bouck N, Stellmach V, Hsu SC, 1996 How tumors become angiogenic. Adv. Cancer Res 69: 135–174.
Neufeld G, Cohen T, Gengnnovitch S, Poltorak Z, 1999 Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 13: 9–22.
Dvorak HF, 2002 Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 20: 4368–4380.
Ferrara N, Houck K, Jakeman L, Leung DW, 1992 Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocrine Rev 13: 18–32.
Das R, Vonderhaar BK, 1997 Prolactin as a mitogen in mammary cells. J Mammary Gland Biol Neoplasia 2: 29–39.
Clevenger CV, Furth PA, Hankinson SE, Schuler LA, 2003 Role of prolactin in mammary carcinoma. Endocr Rev 24: 1–27.
Clapp C, Lopez-Gomez FJ, Nava G, et al, 1998 Expression of prolactin mRNA and of prolactin-like proteins in endothelial cells: Evidence for autocrine effects. J Endocrinol 158: 137–144.
Tabruyn SP, Nguyen NQ, Cornet AM, Martial JA, Struman I, 2005 The antiangiogenic factor, 16-kDa human prolactin, induces endothelial cell cycle arrest by acting at both the G0-G1 and the G2-M phases. Mol Endocrinol 19: 1932–1942.
Lloyd RV, Vidal S, Horvath E, Kovacs K, Scheithauer BW, 2003 Angiogenesis in normal and neoplastic pituitary tissues. Microsc Res Tech 60: 244–250.
Vidal S, Scheithauer BW, Kovacs K, 2000 Vascularity in nontumorous human pituitaries and incidental microadenomas: a morphometric study. Endocr Pathol 11: 215–227.
Hickey MM, Simon MC, 2006 Regulation of angiogenesis by hypoxia and hypoxia-inducible factors. Curr Top Dev Biol 76: 217–257.